A Live Attenuated Sars-Cov-2 and a Vaccine Made Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a live attenuated SARS-CoV-2 vaccine developed through a method called codon-pair deoptimization, which changes the genetic code of the virus to reduce its ability to replicate and cause disease, while keeping its proteins the same as the wild type. The resulting weakened virus can stimulate a strong and broad immune response without causing severe disease. The patent also covers the methods of producing the virus, making pharmaceutical compositions with it, and administering it for vaccination in humans or animals.

Use CasesContent extracted from patent full text and abstract with AI.

• Human vaccination against COVID-19 and its variants, including Alpha, Beta, Gamma, Delta, and Omicron.
• Vaccination of animals susceptible to SARS-CoV-2 (e.g., rodents, other mammals).
• Development of intranasal or oral vaccines for mucosal immunity.
• Boosting previous vaccination induced by other platforms (e.g., mRNA, adenoviral, inactivated vaccines).
• Preclinical models and research to study immune responses to live attenuated coronavirus vaccines.

BenefitsContent extracted from patent full text and abstract with AI.

• Potential for single-dose administration with robust, durable protection.
• Targets multiple viral proteins, inducing broad immune responses, which may provide better protection against variants than spike-only vaccines.
• Can be delivered intranasally or orally, simulating natural infection and providing mucosal immunity.
• Lower risk of severe side effects compared to wild-type infection; attenuated viruses are designed to be safe and not cause disease.
• Simple and scalable production process suitable for low-resource settings; stable for transport and storage, aiding in global distribution.
• Unlikely to revert to virulence due to the large number of stable genetic changes introduced by codon-pair deoptimization.
• Potential reduction in virus transmission due to mucosal immunity and local protection in the airways.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein (7), non-structural protein (8), non-structural protein (9), non-structural protein (10), non-structural protein (11), non-structural protein (12), an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS-CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.